(Q39463711)

12 September 2017

Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo (English)

1 reference

12 September 2017

1 reference

1 reference

J Y Henry

1

1 reference

12 September 2017

L Lu

2

1 reference

12 September 2017

M Adams

3

1 reference

12 September 2017

B Meyer

4

1 reference

12 September 2017

J B Bartlett

5

1 reference

12 September 2017

A G Dalgleish

6

1 reference

12 September 2017

C Galustian

7

1 reference

12 September 2017

language of work or name

1 reference

3 October 2011

1 reference

12 September 2017

1 reference

12 September 2017

72

1 reference

12 September 2017

8

1 reference

12 September 2017

856-867

1 reference

Chemotherapy for the treatment of hormone-refractory prostate cancer

12 September 2017

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21488

Managing the local complications of locally advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21488

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21488

Drug insight: Use of docetaxel in prostate and urothelial cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21488

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21488

Thalidomide-derived immunomodulatory drugs as therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21488

The evolution of thalidomide and its IMiD derivatives as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21488

Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21488

Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21488

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21488

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21488

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21488

Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21488

Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21488

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21488

Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21488

Tumor doubling time of renal cell carcinoma measured by CT: collaboration of Japanese Society of Renal Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21488

Enhancing the cytotoxic activity of novel targeted therapies--is there a role for a combinatorial approach?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21488

Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21488

2-chloroadenosine modulates PAR-1 and IL-23 expression and enhances docetaxel effects on PC3 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21488

Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21488

Inhibition of p38 MAPK suppresses inflammatory cytokine induction by etoposide, 5-fluorouracil, and doxorubicin without affecting tumoricidal activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21488

Overcoming drug resistance in hormone- and drug-refractory prostate cancer cell line, PC-3 by docetaxel and gossypol combination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21488

Regulation of apoptosis-related molecules by synergistic combination of all-trans retinoic acid and zoledronic acid in hormone-refractory prostate cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21488

Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21488

Angiogenic potential of prostate carcinoma cells overexpressing bcl-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21488

The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21488

Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21488

Two different forms of p53 localized differently within cells of urogenital tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21488

Oscillations of the p53-Akt network: implications on cell survival and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21488

Reduced expression of p27 is a novel mechanism of docetaxel resistance in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21488

Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21488

p53 and Bad: remote strangers become close friends

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.21488

21 January 2018

Identifiers

DOI

10.1002/PROS.21488

1 reference

12 September 2017

1 reference